Ansa Biotechnologies has raised $71.5 million in an oversubscribed Series C round, bringing its total funding to $211 million. Blue Water Life Science Advisors led the financing. New investors included Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital. Existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures also participated.
Ansa plans to use the funding to expand manufacturing capacity, serve additional customers, and extend its ability to produce long and complex synthetic DNA.
Enzymatic Synthesis Supports Complex DNA Designs
AI-enabled drug discovery and computational biology can produce increasingly ambitious genetic designs, but researchers still need to manufacture physical DNA to test those concepts.
Conventional synthesis techniques can face limitations involving sequence length, complexity, reliability, and delivery schedules.
Ansa’s enzymatic synthesis platform is designed to produce sequences that are difficult to manufacture through traditional methods.
The company offers sequence-perfect clonal DNA up to 50 kilobases and sequence-verified linear double-stranded DNA fragments.
Its products support drug discovery, vaccines, cell and gene therapies, agrigenomics, and other biological research.
The company applies biosecurity screening to every order.
Ansa also offers an on-time guarantee providing a committed shipping date. If the complete order does not ship by that date, the customer receives it without charge.
Manufacturing Capacity Quadrupled During Previous Year
Ansa quadrupled its manufacturing capacity during the prior year in response to customer demand.
The new financing will support another stage of operating scale as researchers request longer and more technically challenging sequences.
Three executives have joined the company’s board.
Illumina Ventures founding partner Nick Naclerio brings experience in life science company development and commercialization. Brad Crutchfield, an independent director, previously held senior commercial leadership roles at 10x Genomics, Bio-Rad Laboratories, QIAGEN, and Illumina.
Blue Water founder and Chief Investment Officer Nate Cornell adds more than 25 years of capital markets experience. BEVC co-founder Rowan Chapman has joined as a board observer.
Matthew McManus is stepping down after serving on Ansa’s board for three years.
KEY QUOTES:
Ansa gives researchers access to DNA that has historically been difficult, if not impossible, to obtain, with a delivery commitment they can plan around.
Dr. Nick Naclerio, Founding Partner of Illumina Ventures
The full potential of AI-enabled biology depends on the ability to build and test what computational models design. Ansa gives researchers access to DNA that has historically been difficult, if not impossible, to obtain, with a delivery commitment they can plan around. That combination of technical capability and commercial execution is why we invested.
Dr. Nick Naclerio, Founding Partner of Illumina Ventures
We have believed in Ansa’s vision to transform DNA synthesis from the beginning, and we’re excited to continue supporting the team as they bring that vision to life. Ansa’s powerful platform has the potential to push the boundaries of digital biology and enable the next generation of breakthroughs. This latest financing round will help the company expand its capabilities and scale operations to meet growing customer demand.
Nate Cornell, Founder and Chief Investment Officer of Blue Water Life Science Advisors
Researchers are coming to Ansa with increasingly ambitious designs and a straightforward expectation: deliver the DNA. Our growth reflects the demand unlocked when scientists can reliably obtain sequences that previously held their projects back. This oversubscribed financing validates our commercial success and gives us the resources to expand our capacity, serve more customers, and drive the next generation of biological innovation.
Jason T. Gammack, CEO of Ansa Biotechnologies
Nick and Brad have helped build some of the most consequential life science tools businesses. They understand the operational and commercial demands of rapid growth, and their experience will be invaluable as we scale Ansa. We are also pleased to welcome Nate as a board member and Rowan as a board observer and look forward to her perspective and guidance.
Jason T. Gammack, CEO of Ansa Biotechnologies
Matt has been an important part of Ansa’s journey and helped build the foundation for our growing commercial business. We are grateful for his leadership and support over the past three years.
Jason T. Gammack, CEO of Ansa Biotechnologies

